+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pyelonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 70 Pages
  • May 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5602748
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest disease pipeline guide Pyelonephritis - Drugs In Development, 2022, provides an overview of the Pyelonephritis (Infectious Disease) pipeline landscape.

Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in urethra or bladder and travels up into kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion and back pain or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract and damage to nerves around the bladder. Treatment includes antibiotics.

Report Highlights


The publisher's latest pipeline guide Pyelonephritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pyelonephritis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pyelonephritis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 2, 6, 4, 2, 1 and 1 respectively.

Pyelonephritis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pyelonephritis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pyelonephritis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pyelonephritis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pyelonephritis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pyelonephritis (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pyelonephritis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pyelonephritis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of TablesList of FiguresIntroduction
Report Coverage
Pyelonephritis - Overview
Pyelonephritis - Therapeutics Development
Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Pyelonephritis - Therapeutics Assessment
Assesement by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pyelonephritis - Companies Involved in Therapeutics Development
Achaogen Inc (Inactive)
Allecra Therapeutics GmbH
Entasis Therapeutics Holdings Inc
Iterum Therapeutics Plc
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
Nabriva Therapeutics Plc
Paratek Pharmaceuticals Inc
Pfizer Inc
Qilu Pharmaceutical Co Ltd
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
XuanZhu Biological Technology Co Ltd
Pyelonephritis - Drug Profiles
(AAI-101 + cefepime) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(avibactam sodium + ceftazidime) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(cefepime + taniborbactam hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(cefepime + zidebactam) - Drug Profile
Product Description
Mechanism Of Action
(ceftolozane sulfate + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(durlobactam sodium + sulbactam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(meropenem + vaborbactam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
benapenem - Drug Profile
Product Description
Mechanism Of Action
History of Events
ceforanide - Drug Profile
Product Description
Mechanism Of Action
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
History of Events
FL-058 - Drug Profile
Product Description
Mechanism Of Action
History of Events
fosfomycin disodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
nacubactam - Drug Profile
Product Description
Mechanism Of Action
History of Events
omadacycline tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
plazomicin sulfate - Drug Profile
Product Description
Mechanism Of Action
History of Events
sulopenem - Drug Profile
Product Description
Mechanism Of Action
History of Events
tebipenem pivoxil hydrobromide - Drug Profile
Product Description
Mechanism Of Action
History of Events
WCK-6777 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Pyelonephritis - Dormant Projects
Pyelonephritis - Discontinued Products
Pyelonephritis - Product Development Milestones
Featured News
Apr 06, 2022: Spero Therapeutics tebipenem pivoxil hydrobromide phase 3 data published in The New England Journal of Medicine
Jan 03, 2022: Spero Therapeutics announces FDA acceptance and Priority Review of New Drug Application for Tebipenem HBr for the treatment of complicated urinary tract infections including pyelonephritis
Oct 28, 2021: Spero Therapeutics submits new drug application to U.S. FDA for tebipenem HBr for the treatment of complicated urinary tract infections including pyelonephritis
Sep 16, 2021: Spero Therapeutics to present data at IDWeek 2021
Dec 16, 2020: Class 2 medicines recall: Merck Sharp & Dohme, Zerbaxa 1g/0.5g powder for concentrate for solution for infusion
Oct 21, 2020: Key highlights include data on NUZYRA as an alternative to standard of care to reduce clostridioides difficile infections and real-world experience with NUZYRA for nontuberculous mycobacterial and MDR/XDR gram negative infections
Oct 16, 2020: Spero Therapeutics to present data on tebipenem HBr at IDWeek 2020
Sep 18, 2020: AstraZeneca receives CHMP positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Zavicefta
Sep 08, 2020: Spero Therapeutics announces positive topline results from its phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis
Jun 25, 2020: CHMP recommended extensions of indication for Zavicefta
Apr 20, 2020: Wockhardt receives US FDA Qualified Infectious Disease Product designation for WCK 6777, a first ever once-a-day ß-lactam enhancer class antibiotic
Feb 25, 2020: Allecra Therapeutics announces positive top-line results for Phase 3 ALLIUM clinical trial of EXBLIFEP for complicated urinary tract infections
Sep 03, 2019: Allecra Therapeutics to present data at ASM/ESCMID 2019 Conference on drug development to meet the challenge of antimicrobial resistance
Jul 29, 2019: Merck receives positive EU CHMP opinion for ZERBAXA 3g dose (ceftolozane and tazobactam) for the treatment of adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)
Apr 15, 2019: Paratek Pharmaceuticals broadens clinical profile of NUZYRA (Omadacycline) with New ECCMID 2019 Data Presentations
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer
List of Tables
  • Number of - Products under Development for Pyelonephritis, 2022
  • Number of - Products under Development by Companies, 2022
  • Products under Development by Companies, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
Pyelonephritis - Pipeline by Achaogen Inc (Inactive), 2022
Pyelonephritis - Pipeline by Allecra Therapeutics GmbH, 2022
Pyelonephritis - Pipeline by Entasis Therapeutics Holdings Inc, 2022
Pyelonephritis - Pipeline by Iterum Therapeutics Plc, 2022
Pyelonephritis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, 2022
Pyelonephritis - Pipeline by Meiji Seika Pharma Co Ltd, 2022
Pyelonephritis - Pipeline by Melinta Therapeutics Inc, 2022
Pyelonephritis - Pipeline by Merck & Co Inc, 2022
Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, 2022
Pyelonephritis - Pipeline by Nabriva Therapeutics Plc, 2022
Pyelonephritis - Pipeline by Paratek Pharmaceuticals Inc, 2022
Pyelonephritis - Pipeline by Pfizer Inc, 2022
Pyelonephritis - Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Pyelonephritis - Pipeline by VenatoRx Pharmaceuticals Inc, 2022
Pyelonephritis - Pipeline by Wockhardt Ltd, 2022
Pyelonephritis - Pipeline by XuanZhu Biological Technology Co Ltd, 2022
Pyelonephritis - Dormant Projects, 2022
Pyelonephritis - Discontinued Products, 2022
List of Figures
  • Number of - Products under Development for Pyelonephritis, 2022
  • Number of - Products under Development by Companies, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Stage and Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Achaogen Inc (Inactive)
  • Allecra Therapeutics GmbH
  • Entasis Therapeutics Holdings Inc
  • Iterum Therapeutics Plc
  • Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Merck & Co Inc
  • MerLion Pha